Ethypharm could be up for sale; Oncoceutics closes a Series A;

@FierceBiotech: Take the poll: Has the biotech boom come to an end? More | Follow @FierceBiotech

@JohnCFierce: Sold out the Fierce London biotech conference, which is cool. Thank you, U.K. More | Follow @JohnCFierce

> The private equity owners of French drugmaker Ethypharm are considering selling the company, Bloomberg reports. News

> Biotech startup Oncoceutics raised an undisclosed sum in a Series A financing round, developing a novel treatment for cancer. More

> Valeant Pharmaceuticals ($VRX), under fire for its business model, is insisting its drug price increases are not as dramatic as is portrayed by media and lawmakers. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Baxter, Boston Sci back TVA in $15M round to ease hemodialysis vascular access. Report | Follow @FierceMedDev

@VarunSaxena2: #AdvaMed15: Director of  says local coverage decisions are varying by locality. Not all geographies reimburse Dx tests the same way. | Follow @VarunSaxena2

@EmilyWFierce: Sold on diabetes tech, Joslin tests mobile app for Type 1 patients. FiercePharmaMarketing story | Follow @EmilyWFierce

> OptiNose raises up to $30M to get drug-device combo through FDA. Story

> Stratatech nabs $247M BARDA contract for skin tissue device. Article

Pharma News

@FiercePharma: Something's got to give in India's pharma policy contradictions. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: AmerisourceBergen looks for compound interest with its $2.5B deal to buy PharMEDium. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Investors cheer as Arena forces out CEO and cofounder. More | Follow @CarlyHFierce

> U.K. cost gatekeeper says 'OK' to Merck's Keytruda for advanced skin cancer. Story

> Valeant hits back at price-hike critics amid national scrutiny. Article

> Two's company for PCSK9 meds as Praluent, Repatha both nab coverage from top PBM. More

Biotech Research News

> Rutgers researchers make headway with an HDAC inhibitor for Alzheimer's. More

> Alzheimer's: Investigators spotlight a pathway for amyloid beta clearance. Report

> Penn team shines a light on blood disorder. Item

> UCSC team reveals key structural component in telomerase enzyme. Story

> NIH researchers' new mouse model points to a gene therapy for eye disease. Article

Diagnostics News

> Myriad inks coverage deal for prostate cancer test. Item

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Report

> Cancer Genetics makes strides in $14M deal for Response Genetics. More

> Invitae doubles genetic testing menu with cancer, neuromuscular offerings. Article

> Illumina expands in China with cancer Dx deal. Story

Pharma Marketing News

> Can Daklinza profit from a set of niche hep C uses? BMS may soon find out. Item

> Bristol-Myers shells out $14.7M in China bribery settlement. More

> British docs weigh in on pharma, and it's no better than most U.S. opinions. Report

> The data difference? Publicis adds data practice to sharpen healthcare media buying and planning. Story

> Glaxo OTC chief: When it comes to consumer health, pharma has the edge. Article

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.